Limits...
Surface protein mutations in chronic hepatitis B patients who received hepatitis B vaccine therapy.

Daram M, Montazeri G, Karimzadeh H, Malekzadeh R, Mahmoodi M, Goodarzi Z, Keyvani H, Mirmomen S, Alavian SM, Roggendorf M, Jazayeri SM - Iran J Basic Med Sci (2014)

Bottom Line: In the control group, 35 and 41 amino acid substitutions were found before and after therapy, respectively. 32 (42%) of 76 amino acid changes occurred within immune epitopes.There were no differences in age, gender, and duration of chronicity in both patient and control groups in terms of the frequency and the patterns of mutations.Newer strategies should be considered based on third generation or the use of DNA vaccines or new adjuvants.

View Article: PubMed Central - PubMed

Affiliation: Hepatitis B Molecular Laboratory, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

ABSTRACT

Objective s: The aim of this study was to determine the correlation between vaccine therapy and appearance of mutations in hepatitis B surface antigen (HBsAg)-positive chronic hepatitis B virus (HBV) patients.

Materials and methods: 16 patients received the HBV vaccine and another 16 individuals from the control group did not. The surface gene was amplified and directly sequenced from samples prior to vaccination and six months after the third dose.

Results: Only one patient lost HBsAg. 48 and 44 amino acid mutations were found before and after vaccine therapy in the vaccine group respectively, 51 of which (55.4%) occurred in immune epitopes: 5 were in B cell, 21 in T helper (Th), and 25 in cytotoxic T-lymphocyte (CTL) epitopes. In the control group, 35 and 41 amino acid substitutions were found before and after therapy, respectively. 32 (42%) of 76 amino acid changes occurred within immune epitopes. There were no differences in age, gender, and duration of chronicity in both patient and control groups in terms of the frequency and the patterns of mutations.

Conclusion: In chronic carriers who already had HBsAg variants selected by the host-immune response, any immune stimulation by the vaccine had no effect on the chronic state of these patients or selected any remarkable escape mutants. Newer strategies should be considered based on third generation or the use of DNA vaccines or new adjuvants.

No MeSH data available.


Related in: MedlinePlus

Position of amino acid and numberof mutations at immuno epitopes in control group before and after therapy
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4322145&req=5

Figure 3: Position of amino acid and numberof mutations at immuno epitopes in control group before and after therapy

Mentions: Thirty-five and forty-one amino acid mutations were found before and after the period of vaccine therapy. Similarly, 32 (42%) of 76 amino acid changes which occurred within immune epitopes, 4 (12.5%) occurred in B cell epitopes affecting 4 residues; 14 (43.7%) occurred in the T helper epitopes affecting 9 residues and 14 (43.7%) occurred in 3 residues inside the CTL epitopes (Table 2, Figure 3).


Surface protein mutations in chronic hepatitis B patients who received hepatitis B vaccine therapy.

Daram M, Montazeri G, Karimzadeh H, Malekzadeh R, Mahmoodi M, Goodarzi Z, Keyvani H, Mirmomen S, Alavian SM, Roggendorf M, Jazayeri SM - Iran J Basic Med Sci (2014)

Position of amino acid and numberof mutations at immuno epitopes in control group before and after therapy
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4322145&req=5

Figure 3: Position of amino acid and numberof mutations at immuno epitopes in control group before and after therapy
Mentions: Thirty-five and forty-one amino acid mutations were found before and after the period of vaccine therapy. Similarly, 32 (42%) of 76 amino acid changes which occurred within immune epitopes, 4 (12.5%) occurred in B cell epitopes affecting 4 residues; 14 (43.7%) occurred in the T helper epitopes affecting 9 residues and 14 (43.7%) occurred in 3 residues inside the CTL epitopes (Table 2, Figure 3).

Bottom Line: In the control group, 35 and 41 amino acid substitutions were found before and after therapy, respectively. 32 (42%) of 76 amino acid changes occurred within immune epitopes.There were no differences in age, gender, and duration of chronicity in both patient and control groups in terms of the frequency and the patterns of mutations.Newer strategies should be considered based on third generation or the use of DNA vaccines or new adjuvants.

View Article: PubMed Central - PubMed

Affiliation: Hepatitis B Molecular Laboratory, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

ABSTRACT

Objective s: The aim of this study was to determine the correlation between vaccine therapy and appearance of mutations in hepatitis B surface antigen (HBsAg)-positive chronic hepatitis B virus (HBV) patients.

Materials and methods: 16 patients received the HBV vaccine and another 16 individuals from the control group did not. The surface gene was amplified and directly sequenced from samples prior to vaccination and six months after the third dose.

Results: Only one patient lost HBsAg. 48 and 44 amino acid mutations were found before and after vaccine therapy in the vaccine group respectively, 51 of which (55.4%) occurred in immune epitopes: 5 were in B cell, 21 in T helper (Th), and 25 in cytotoxic T-lymphocyte (CTL) epitopes. In the control group, 35 and 41 amino acid substitutions were found before and after therapy, respectively. 32 (42%) of 76 amino acid changes occurred within immune epitopes. There were no differences in age, gender, and duration of chronicity in both patient and control groups in terms of the frequency and the patterns of mutations.

Conclusion: In chronic carriers who already had HBsAg variants selected by the host-immune response, any immune stimulation by the vaccine had no effect on the chronic state of these patients or selected any remarkable escape mutants. Newer strategies should be considered based on third generation or the use of DNA vaccines or new adjuvants.

No MeSH data available.


Related in: MedlinePlus